Modified release preparations containing oxcarbazepine and derivatives thereof
Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
1. A pharmaceutical formulation for once-a-day administration of oxcarbazepine comprising multiple units, wherein each unit comprises a homogeneous mixture of (a) oxcarbazepine, (b) at least one agent that enhances solubility of oxcarbazepine, and (c) at least one release promoting agent, wherein said release promoting agent comprises a polymer having pH-dependent solubility, and wherein each unit has a release profile for the oxcarbazepine different from other units.
2. The pharmaceutical formulation of claim 1 wherein said agent that enhances solubility of oxcarbazepine is selected from a group comprising surface active agents, complexing agents, cyclodextrins, pH modifying agents, and hydration promoting agents.
3. The pharmaceutical formulation of claim 2 wherein said surface active agents are selected from a group comprising sodium docusate, sodium lauryl sulfate, sodium stearyl fumarate, polyethylene oxide (PEO) modified sorbitan monoesters, fatty acid sorbitan esters, and polyethylene oxide-polypropylene oxide-(poly(ethylene oxide)) block copolymers.
4. The pharmaceutical formulation of claim 1 , wherein at least one unit comprises a matrix forming polymer selected from a group comprising swellable polymers and gel-forming polymers.
5. The pharmaceutical formulation of claim 4 wherein the matrix forming polymer is selected from a group comprising cellulosic polymers, alginates, gums, cross-linked polyacrylic acids, carageenan; polyvinyl pyrrolidone; polyethylene oxides; and polyvinyl alcohol.
6. The pharmaceutical formulation of claim 1 , the polymer having pH dependent solubility remains intact at pH values of below 4, and dissolves at pH values of more than 4.
7. The pharmaceutical formulation of claim 6 , wherein the polymer having pH dependent solubility dissolves at pH values of more than 5.
8. The pharmaceutical formulation of claim 6 , wherein the polymer having pH dependent solubility dissolves at pH values of more than 6.
9. The pharmaceutical formulation of claim 1 , wherein the polymer having pH dependent solubility comprises cellulose acetate phthalate, cellulose acetate succinate, methylcellulose phthalate, ethylhydroxycellulose phthalate, polyvinylacetate phthalate, polyvinylbutyrate acetate, vinyl acetate-maleic anhydride copolymer, styrene-maleic mono-ester copolymer, or methyl acrylate-methacrylic acid copolymers.
10. The pharmaceutical formulation of claim 1 , wherein the amount of the release promoting agent is from 10% to 90% by weight, and the amount of the solubilizing agent can be from 1% to 80% by weight of a dosage form.
11. The pharmaceutical formulation of claim 10 , wherein the amount of the release promoting agent is from 30% to 70% by weight, and the amount of the solubilizing agent can be from 1% to 50% by weight of the dosage form.
12. A pharmaceutical formulation for once-a-day administration of oxcarbazepine comprising multiple units, wherein each unit comprises a homogeneous mixture of (a) oxcarbazepine, (b) at least one agent that enhances solubility of oxcarbazepine, and (c) at least one release promoting agent, wherein said release promoting agent comprises a polymer having pH-dependent solubility, wherein each unit has a release profile for the oxcarbazepine different from other units, and wherein the amount of oxcarbazepine is effective to produce a steady state blood level of monohydroxy derivative of oxcarbazepine in the range of about 2 μg/ml to about 10 μg/ml.
13. The pharmaceutical formulation of claim 12 , wherein C max levels of monohydroxy derivative of oxcarbazepine (MHD) are in the range of about 6 μg/ml to about 10 μg/ml and C min levels of MHD are in the range of about 2 μg/ml to about 5 μg/ml.
14. The pharmaceutical formulation of claim 1 , which exhibits for an initial immediate release of oxcarbazepine followed by a modified release of oxcarbazepine.
15. The pharmaceutical formulation of claim 14 , wherein said modified release comprises a delayed release, an extended release, or a combination of delayed and extended release, each release characterized by a different release rate profile.
16. The pharmaceutical formulation of claim 1 , which comprises multiple units having a modified release profile.
17. The pharmaceutical formulation of claim 16 , wherein said modified release profile is selected from a group comprising a delayed release profile, an extended release profile, and a combination of any number of delayed and extended release profiles, each characterized by a different release rate.
18. The pharmaceutical formulation of claim 17 , wherein said units are in the form of minipellets, minigranules, minitablets and layers.
19. The pharmaceutical formulation of claim 1 in the form of pellets, tablets, granules or capsules.
20. The formulation of claim 1 , wherein at least one unit comprises a release modifying coating.
21. The formulation of claim 1 , which exhibits reduced side-effects.
22. A pharmaceutical formulation for once-a-day administration of oxcarbazepine comprising multiple units, wherein each unit consists essentially of a matrix comprising a homogenous mixture of oxcarbazepine, at least one agent that enhances solubility of oxcarbazepine, and at least one release promoting agent, wherein said release promoting agent comprises a polymer having pH-dependent solubility, and wherein each unit has a release profile for the oxcarbazepine different from other units.